Active Gα_i/o Mutants Accelerate Breast Tumor Metastasis via the c-Src Pathway

REFERENCES

• Bhushan A, Gonsalves A, Menon JU. Current state of breast cancer diagnosis, treatment, and theranostics. Pharmaceutics. 2021;13:723. doi:10.3390/pharmaceutics13050723.
   PubMed Web of Science ®Google Scholar
• Campbell AP, Smrcka AV. Targeting G protein-coupled receptor signalling by blocking G proteins. Nat Rev Drug Discov. 2018;17:789–803. doi:10.1038/nrd.2018.135.
   PubMed Web of Science ®Google Scholar
• Oldham WM, Hamm HE. Heterotrimeric G protein activation by G-protein-coupled receptors. Nat Rev Mol Cell Biol. 2008;9:60–71. doi:10.1038/nrm2299.
   PubMed Web of Science ®Google Scholar
• Smrcka AV. Molecular targeting of Galpha and Gbetagamma subunits: a potential approach for cancer therapeutics. Trends Pharmacol Sci. 2013;34:290–298. doi:10.1016/j.tips.2013.02.006.
   PubMed Web of Science ®Google Scholar
• Arang N, Gutkind JS. G Protein-Coupled receptors and heterotrimeric G proteins as cancer drivers. FEBS Lett. 2020;594:4201–4232. doi:10.1002/1873-3468.14017.
   PubMed Web of Science ®Google Scholar
• Wu V, Yeerna H, Nohata N, Chiou J, Harismendy O, Raimondi F, Inoue A, Russell RB, Tamayo P, Gutkind JS. Illuminating the Onco-GPCRome: novel G protein-coupled receptor-driven oncocrine networks and targets for cancer immunotherapy. J Biol Chem. 2019;294:11062–11086. doi:10.1074/jbc.REV119.005601.
   PubMed Web of Science ®Google Scholar
• Feng X, Degese MS, Iglesias-Bartolome R, Vaque JP, Molinolo AA, Rodrigues M, Zaidi MR, Ksander BR, Merlino G, Sodhi A, et al. Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry. Cancer Cell. 2014;25:831–845. doi:10.1016/j.ccr.2014.04.016.
   PubMed Web of Science ®Google Scholar
• Ideno N, Yamaguchi H, Ghosh B, Gupta S, Okumura T, Steffen DJ, Fisher CG, Wood LD, Singhi AD, Nakamura M, et al. GNAS(R201C) induces pancreatic cystic neoplasms in mice that express activated KRAS by inhibiting YAP1 signaling. Gastroenterology. 2018;155:1593–1607.e12. doi:10.1053/j.gastro.2018.08.006.
   PubMed Web of Science ®Google Scholar
• Patra KC, Kato Y, Mizukami Y, Widholz S, Boukhali M, Revenco I, Grossman EA, Ji F, Sadreyev RI, Liss AS, et al. Mutant GNAS drives pancreatic tumourigenesis by inducing PKA-mediated SIK suppression and reprogramming lipid metabolism. Nat Cell Biol. 2018;20:811–822. doi:10.1038/s41556-018-0122-3.
   PubMed Web of Science ®Google Scholar
• Van Raamsdonk CD, Bezrookove V, Green G, Bauer J, Gaugler L, O’Brien JM, Simpson EM, Barsh GS, Bastian BC. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature. 2009;457:599–602. doi:10.1038/nature07586.
   PubMed Web of Science ®Google Scholar
• Van Raamsdonk CD, Griewank KG, Crosby MB, Garrido MC, Vemula S, Wiesner T, Obenauf AC, Wackernagel W, Green G, Bouvier N, et al. Mutations in GNA11 in uveal melanoma. N Engl J Med. 2010;363:2191–2199. doi:10.1056/NEJMoa1000584.
   PubMed Web of Science ®Google Scholar
• Wilson CH, McIntyre RE, Arends MJ, Adams DJ. The activating mutation R201C in GNAS promotes intestinal tumourigenesis in Apc(Min/+) mice through activation of Wnt and ERK1/2 MAPK pathways. Oncogene. 2010;29:4567–4575. doi:10.1038/onc.2010.202.
   PubMed Web of Science ®Google Scholar
• Lyons J, Landis CA, Harsh G, Vallar L, Grunewald K, Feichtinger H, Duh QY, Clark OH, Kawasaki E, Bourne HR. Two G protein oncogenes in human endocrine tumors. Science. 1990;249:655–659. doi:10.1126/science.2116665.
   PubMed Web of Science ®Google Scholar
• Garcia-Marcos M, Ghosh P, Farquhar MG. Molecular basis of a novel oncogenic mutation in GNAO1. Oncogene. 2011;30:2691–2696. doi:10.1038/onc.2010.645.
   PubMed Web of Science ®Google Scholar
• Kan Z, Jaiswal BS, Stinson J, Janakiraman V, Bhatt D, Stern HM, Yue P, Haverty PM, Bourgon R, Zheng J, et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature. 2010;466:869–873. doi:10.1038/nature09208.
   PubMed Web of Science ®Google Scholar
• Song L, Yu B, Yang Y, Liang J, Zhang Y, Ding L, Wang T, Wan X, Yang X, Tang J, et al. Identification of functional cooperative mutations of GNAO1 in human acute lymphoblastic leukemia. Blood. 2021;137:1181–1191. doi:10.1182/blood.2020005622.
   PubMed Web of Science ®Google Scholar
• Lyu C, Ye Y, Lensing MM, Wagner KU, Weigel RJ, Chen S. Targeting Gi/o protein-coupled receptor signaling blocks HER2-induced breast cancer development and enhances HER2-targeted therapy. JCI Insight. 2021;6:e150532. doi:10.1172/jci.insight.150532.
   PubMed Web of Science ®Google Scholar
• Lyu C, Ye Y, Weigel RJ, Chen S. Blocking Gi/o-coupled signaling eradicates cancer stem cells and sensitizes breast tumors to HER2-targeted therapies to inhibit tumor relapse. Cancers (Basel). 2022;14:1719. doi:10.3390/cancers14071719.
   PubMed Web of Science ®Google Scholar
• Kirui JK, Xie Y, Wolff DW, Jiang H, Abel PW, Tu Y. Gbetagamma signaling promotes breast cancer cell migration and invasion. J Pharmacol Exp Ther. 2010;333:393–403. doi:10.1124/jpet.109.164814.
   PubMed Web of Science ®Google Scholar
• Tang X, Sun Z, Runne C, Madsen J, Domann F, Henry M, Lin F, Chen S. A critical role of Gbetagamma in tumorigenesis and metastasis of breast cancer. J Biol Chem. 2011;286:13244–13254. doi:10.1074/jbc.M110.206615.
   PubMed Web of Science ®Google Scholar
• Shajahan AN, Tiruppathi C, Smrcka AV, Malik AB, Minshall RD. Gbetagamma activation of Src induces caveolae-mediated endocytosis in endothelial cells. J Biol Chem. 2004;279:48055–48062. doi:10.1074/jbc.M405837200.
   PubMed Web of Science ®Google Scholar
• Ma YC, Huang J, Ali S, Lowry W, Huang XY. Src tyrosine kinase is a novel direct effector of G proteins. Cell. 2000;102:635–646. doi:10.1016/s0092-8674(00)00086-6.
   PubMed Web of Science ®Google Scholar
• Grishina G, Berlot CH. Identification of common and distinct residues involved in the interaction of alphai2 and alphas with adenylyl cyclase. J Biol Chem. 1997;272:20619–20626. doi:10.1074/jbc.272.33.20619.
   PubMed Web of Science ®Google Scholar
• Dbouk HA, Backer JM. A beta version of life: p110beta takes center stage. Oncotarget. 2010;1:729–733. doi:10.18632/oncotarget.101205.
   PubMedGoogle Scholar
• Khalil BD, Hsueh C, Cao Y, Abi Saab WF, Wang Y, Condeelis JS, Bresnick AR, Backer JM. GPCR signaling mediates tumor metastasis via PI3Kbeta. Cancer Res. 2016;76:2944–2953. doi:10.1158/0008-5472.CAN-15-1675.
   PubMedGoogle Scholar
• Ye Y, Tang X, Sun Z, Chen S. Upregulated WDR26 serves as a scaffold to coordinate PI3K/AKT pathway-driven breast cancer cell growth, migration, and invasion. Oncotarget. 2016;7:17854–17869. doi:10.18632/oncotarget.7439.
   PubMedGoogle Scholar
• Ram PT, Horvath CM, Iyengar R. Stat3-mediated transformation of NIH-3T3 cells by the constitutively active Q205L Galphao protein. Science. 2000;287:142–144. doi:10.1126/science.287.5450.142.
   PubMed Web of Science ®Google Scholar
• Nautiyal J, Majumder P, Patel BB, Lee FY, Majumdar AP. Src inhibitor dasatinib inhibits growth of breast cancer cells by modulating EGFR signaling. Cancer Lett. 2009;283:143–151. doi:10.1016/j.canlet.2009.03.035.
   PubMed Web of Science ®Google Scholar
• Guarino M. Src signaling in cancer invasion. J Cell Physiol. 2010;223:14–26. doi:10.1002/jcp.22011.
   PubMed Web of Science ®Google Scholar
• Martellucci S, Clementi L, Sabetta S, Mattei V, Botta L, Angelucci A. Src family kinases as therapeutic targets in advanced solid tumors: what we have learned so far. Cancers (Basel). 2020;12:1448. doi:10.3390/cancers12061448.
   PubMed Web of Science ®Google Scholar
• Corre I, Baumann H, Hermouet S. Regulation by Gi2 proteins of v-fms-induced proliferation and transformation via Src-kinase and STAT3. Oncogene. 1999;18:6335–6342. doi:10.1038/sj.onc.1203010.
   PubMed Web of Science ®Google Scholar
• Sriram K, Moyung K, Corriden R, Carter H, Insel PA. GPCRs show widespread differential mRNA expression and frequent mutation and copy number variation in solid tumors. PLoS Biol. 2019;17:e3000434. doi:10.1371/journal.pbio.3000434.
   PubMed Web of Science ®Google Scholar
• Mayer EL, Krop IE. Advances in targeting SRC in the treatment of breast cancer and other solid malignancies. Clin Cancer Res. 2010;16:3526–3532. doi:10.1158/1078-0432.CCR-09-1834.
   PubMed Web of Science ®Google Scholar
• Myoui A, Nishimura R, Williams PJ, Hiraga T, Tamura D, Michigami T, Mundy GR, Yoneda T. C-SRC tyrosine kinase activity is associated with tumor colonization in bone and lung in an animal model of human breast cancer metastasis. Cancer Res. 2003;63:5028–5033.
   PubMed Web of Science ®Google Scholar
• Jallal H, Valentino ML, Chen G, Boschelli F, Ali S, Rabbani SA. A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo. Cancer Res. 2007;67:1580–1588. doi:10.1158/0008-5472.CAN-06-2027.
   PubMed Web of Science ®Google Scholar
• Sakamoto K, Schmidt JW, Wagner KU. Generation of a novel MMTV-tTA transgenic mouse strain for the targeted expression of genes in the embryonic and postnatal mammary gland. PLoS One. 2012;7:e43778. doi:10.1371/journal.pone.0043778.
   PubMed Web of Science ®Google Scholar
• Nicholls RE, Zhang XL, Bailey CP, Conklin BR, Kandel ER, Stanton PK. mGluR2 acts through inhibitory Galpha subunits to regulate transmission and long-term plasticity at hippocampal mossy fiber-CA3 synapses. Proc Natl Acad Sci USA. 2006;103:6380–6385. doi:10.1073/pnas.0601267103.
   PubMed Web of Science ®Google Scholar
• Li G, Robinson GW, Lesche R, Martinez-Diaz H, Jiang Z, Rozengurt N, Wagner KU, Wu DC, Lane TF, Liu X, et al. Conditional loss of PTEN leads to precocious development and neoplasia in the mammary gland. Development. 2002;129:4159–4170. doi:10.1242/dev.129.17.4159.
   PubMed Web of Science ®Google Scholar